ACA:EURONEXT PARISCredit Agricole SA Analysis
Data as of 2026-05-19 - not real-time
$117.68
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Arcosa is trading at $117.68, below its 20‑day SMA of 124.36 but comfortably above the 50‑day (114.51) and 200‑day (106.71) averages, suggesting a mild pull‑back within an overall bullish framework. The RSI sits at 43.8, indicating a neutral momentum zone, while a negative MACD histogram signals short‑term bearish pressure. Volume has been decreasing and 30‑day volatility is elevated at roughly 44%, underscoring near‑term price fragility, yet the stock remains above the identified support level of $115.55 and offers an estimated upside of about 20% toward the consensus 12‑month target of $141.
Fundamentally, the company delivered a 4.4% YoY revenue increase to $2.9 bn, with EBITDA climbing to $543 m and margins (gross 22.7%, operating 8.6%) solid for its sector. A forward PE of 23.3 sits below the industry average of 29.3, indicating relative undervaluation, and the modest 0.16% dividend yield is underpinned by a very low payout ratio (~4.5%), making it sustainable. Recent Q1 earnings beat expectations, reporting EPS of $0.77 and strong EBITDA growth, while management raised full‑year guidance, positioning the stock for a measured rally despite a beta near 1.4 and a high fear‑greed index of Extreme Greed.
Fundamentally, the company delivered a 4.4% YoY revenue increase to $2.9 bn, with EBITDA climbing to $543 m and margins (gross 22.7%, operating 8.6%) solid for its sector. A forward PE of 23.3 sits below the industry average of 29.3, indicating relative undervaluation, and the modest 0.16% dividend yield is underpinned by a very low payout ratio (~4.5%), making it sustainable. Recent Q1 earnings beat expectations, reporting EPS of $0.77 and strong EBITDA growth, while management raised full‑year guidance, positioning the stock for a measured rally despite a beta near 1.4 and a high fear‑greed index of Extreme Greed.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price hovering just above the $115.55 support level
- bearish MACD histogram indicating short‑term downside pressure
- decreasing volume combined with high 30‑day volatility
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- PE multiple below industry average suggesting undervaluation
- Q1 earnings beat and raised full‑year guidance
- estimated 20% upside toward the $141 analyst target
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- sustainable dividend supported by a low payout ratio
- strategic divestitures improving the balance sheet
- stable cash flow and long‑term demand for infrastructure solutions
Key Metrics & Analysis
Financial Health
Revenue Growth4.40%
Profit Margin7.66%
P/E Ratio26.3
ROE8.62%
ROA4.00%
Debt/Equity59.55
P/B Ratio2.2
Op. Cash Flow$413.7M
Free Cash Flow$55.3M
Industry P/E29.3
Technical Analysis
TrendBullish
RSI43.8
Support$115.55
Resistance$135.58
MA 20$124.36
MA 50$114.51
MA 200$106.71
MACDBearish
VolumeDecreasing
Fear & Greed Index89.14
Valuation
Target Price$141.00
Upside/Downside19.82%
GradeUndervalued
TypeBlend
Dividend Yield0.16%
Risk Assessment
Beta1.44
Volatility43.58%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.